Allo-SCT for high-risk AML-CR1 in the molecular era: impact of FLT3/ITD outweighs the conventional markers

Myeloablative Reduced-Toxicity i.v. Busulfan-Fludarabine and Allogeneic Hematopoietic Stem Cell Transplant for Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome in the Sixth through Eighth Decades of Life

(2011) Gheath Alatrash et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Role of Allogeneic Transplantation for FLT3/ITD Acute Myeloid Leukemia: Outcomes from 133 Consecutive Newly Diagnosed Patients from a Single Institution

(2011) Amy E. DeZern et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

FLT3/ITD AML and the law of unintended consequences

(2011) M. Levis   BLOOD

Molecular remission of FLT3-ITD+ positive AML relapse after allo-SCT by acute GVHD in addition to sorafenib

(2011) W H Krüger et al.   BONE MARROW TRANSPLANTATION

Donor erythrocytosis induced by sorafenib treatment after allogeneic hematopoietic SCT in a patient with acute myeloid leukemia

(2011) P Chiusolo et al.   BONE MARROW TRANSPLANTATION

Posttransplantation Vaccination: Concepts Today and on the Horizon

(2011) K. Rezvani   Hematology-American Society of Hematology Education Program

NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on the Epidemiology and Natural History of Relapse following Allogeneic Cell Transplantation

(2010) Steven Z. Pavletic et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Transplantation in AML CR1

(2010) B. N. Savani   BLOOD

Toxic effects of sorafenib when given early after allogeneic hematopoietic stem cell transplantation

(2010) H. Yokoyama et al.   BLOOD

Management of relapse after allo-SCT for AML and the role of second transplantation

(2009) B N Savani et al.   BONE MARROW TRANSPLANTATION

Interactive diagnostics in the indication to allogeneic SCT in AML

(2009) U Bacher et al.   BONE MARROW TRANSPLANTATION

Mutations and Treatment Outcome in Cytogenetically Normal Acute Myeloid Leukemia

(2008) Richard F. Schlenk et al.   NEW ENGLAND JOURNAL OF MEDICINE